Effect of HER2 gene on cell proliferation, cell cycle and apoptosis in salivary malignant pleomorphic adenoma

doi:10.19438/j.cjoms.2018.04.004

Abstract

Abstract: PURPOSE:To inhibit HER2 in salivary malignant pleomorphic adenoma, investigate the effect on tumor cell proliferation, cell cycle and apoptosis, and assess the possibility of blocking HER2 to improve MPA malignant biological behavior. METHODS: HER2 expression and proliferation were detected in MPA cell lines. The effect on tumor cell proliferation, cell cycle, apoptosis and down-stream pathway were verified after use of HER2 blockade. SPSS 16.0 software package was used for statistical analysis. RESULTS: HER2 overexpressed/proliferated in SM-AP1 and SM-AP4 cells. By blocking HER2, tumor proliferation and cell cycle were significantly induced, and apoptosis process was activated. In addition, the downstream pathway PI3K/Akt and MAPK/ERK were significantly inhibited. CONCLUSIONS: HER2 overexpressed/proliferated in MPA cell line, which might play an important role in tumor genesis. Inhibiting HER2 might be a novel therapy for poor biological behavior on MPA.

Key words: HER2, Malignant pleomorphic tumor, Salivary gland

CLC Number:

R739.8

XIA Liang, WANG Yang, HU Yu-hua, WANG Li-zhen, GU Ting, LI Jiang, TIAN Zhen. Effect of HER2 gene on cell proliferation, cell cycle and apoptosis in salivary malignant pleomorphic adenoma[J]. China Journal of Oral and Maxillofacial Surgery, 2018, 16(4): 310-316.

References

[1] Hashimoto K, Yamamoto H, Shiratsuchi H, et al.HER-2/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in situ hybridization study[J]. Histopathology, 2012, 60(6B): E131-142.
[2] Tian Z, Li L, Wang L, et al.Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population[J]. Int J Oral Maxillofac Surg, 2010, 39(3): 235-242.
[3] Marx AH, Tharun L, Muth J, et al.HER-2 amplification is highly homogenous in gastric cancer[J]. Hum Pathol, 2009, 40(6): 769-777.
[4] Glisson B, Colevas AD, Haddad R, et al.HER2 expression in salivary gland carcinomas: dependence on histological subtype[J]. Clin Cancer Res, 2004, 10(3): 944-946.
[5] Xia L, Hu Y, Li J, et al.A low percentage of HER-2 amplification whereas indicates poor prognosis in salivary carcinoma ex pleomorphic adenoma: a study of 140 cases[J]. J Oral Pathol Med, 2017, 46(3): 167-174.
[6] Molina MA, Saez R, Ramsey EE, et al.NH₂-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer[J]. Clin Cancer Res, 2002, 8(2): 347-353.
[7] Tevaarwerk AJ, Kolesar JM.Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer[J]. Clin Ther, 2009, 31(Pt 2): 2332-2348.
[8] Maruyama S, Cheng J, Shingaki S, et al.Establishment and characterization of pleomorphic adenoma cell systems: an in-vitro demonstration of carcinomas arising secondarily from adenomas in the salivary gland[J]. BMC Cancer, 2009, 9(2): 247.
[9] Wolff AC, Hammond ME, Hicks DG, et al.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. Arch Pathol Lab Med, 2014, 138(2): 241-256.
[10] Shih J, Bashir B, Gustafson KS, et al.Cancer signature investigation: ERBB2 (HER2)-activating mutation and amplification-positive breast carcinoma mimicking lung primary[J]. J Natl Compr Canc Netw, 2015, 13(8): 947-952.
[11] Ulas A, Kos T, Avci N, et al.Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival[J]. Asian Pac J Cancer Prev, 2015, 16(4): 1643-1649.
[12] Longva KE, Pedersen NM, Haslekås C, et al.Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2[J]. Int J Cancer, 2005, 116(3): 359-367.
[13] Sakai K, Yokote H, Murakami-Murofushi K, et al.Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway[J]. Cancer Sci, 2007, 98(9): 1498-1503.
[14] Zhou X, Tan M, Stone Hawthorne V, et al.Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers[J]. Clin Cancer Res, 2004, 10(20): 6779-6788.
[15] Ohtsuka T, Sakaguchi M, Yamamoto H, et al.Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway[J]. Sci Rep, 2016, 6: 39557.
[16] Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib[J]. Oncologist, 2004, 9(Suppl 3): 10-15.
[17] 马传栋. 拉帕替尼联合硼替佐米抑制乳腺癌细胞生长及硼替佐米对拉帕替尼耐药细胞的活性的研究 [D]. 上海: 复旦大学, 2009.